ASX-Dividend-Report-Banner

Apollo Cancer Centres Collaborates With Accuray to Launch India Sub- Continent's First Robotic Stereotactic Radiotherapy Program

June 26, 2024 03:53 PM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Apollo Cancer Centres Collaborates With Accuray to Launch India Sub- Continent's First Robotic Stereotactic Radiotherapy Program
Image source: Kalkine Media
  • The program will enhance the development of oncology care, thereby, advancing healthcare landscape of the region
  • Participants will engage in in-depth discussions and demonstrations, ensuring a robust and practical learning experience

BANGALORE, India, June 26, 2024 /PRNewswire/ --  Apollo Cancer Centres (ACC), in association with Accuray, a global provider of radiation therapy devices, today announced the launch of India Sub-Continent's first robotic and stereotactic therapy education centre, Robotic & Stereotactic Radiosurgery program . This initiative will be established at ACC in Chennai and Bangalore, and will provide advanced radiosurgery educational training to radiation oncologists, physicists, radiation therapists, and technologists from India and across the India Sub-continent.

Mr Dinesh Madhavan, President Group Oncology, and International, Apollo Hospital Enterprises Ltd, said, "In the field of cancer care ground-breaking technologies pave the way for highly personalized and effective treatment. The inception of the Robotic Stereotactic Radiotherapy Program by Apollo Cancer Centres and Accuray will advance training facilities for the ASEAN region. It will help equip oncologists, physicists, and therapists with the critical knowledge and skills needed to leverage the latest in CyberKnife technology. "

 Dr Sridhar PS, Lead- Cyberknife – Robotic Radiosurgery, said, "The launch of the training program at Apollo Cancer Centre is an exceptional opportunity to enhance skills and knowledge in Robotic & Stereotactic Radiotherapy . Since pioneering the Cyberknife Robotic Radio Surgery System in India and a rich experience of over 5000 patients, we will now share the valuable knowledge in the training program. It will enable oncologists in the development of Cancer care through Cyberknife training."

Ms Suzanne Winter, President & CEO, Accuray, said, "Accuray celebrates the expansion of the CyberKnife® S7™ System to Apollo centers in Chennai and Bangalore, showcasing our enduring collaboration with Apollo Hospitals to enhance cancer care in India. With its unparalleled precision, the CyberKnife S7 System redefines treatment standards, empowering clinicians to optimize outcomes. Additionally, it enables the delivery of high doses of radiation, typically in 1 to 5 sessions for fast and effective treatments, marking a significant advancement in cancer therapy."

The CyberKnife System is a non-invasive, robotic radiation therapy device designed to treat tumors with high precision and minimal damage to surrounding healthy tissue. It uses advanced imaging and computerized robotics to deliver highly focused beams of radiation, allowing for the treatment of complex and hard-to-reach tumors.

With an aim to provide a world-class comprehensive 'Educational Center', the Academia will benefit aspiring CyberKnife clinicians of India and the Subcontinent.

By bringing such a high-caliber educational initiative to India, Apollo Cancer Centres continues to lead the way in medical innovation, dedicated to enhancing the skills of healthcare professionals and ultimately, improving patient outcomes across the country.

#WinningOverCancer

About Apollo Cancer Centre – https://apollocancercentres.com/
THE CANCER CARE LEGACY: BREATHING HOPE INTO LIVES FOR OVER 30 YEARS

Cancer care today means 360-degree comprehensive care, which requires commitment, expertise, and an indomitable spirit from cancer specialists.

Apollo Cancer Centre has a network across India with over 325 oncologists to oversee the delivery of high-end precision Oncology Therapy. Our oncologists deliver world-class cancer care following an organ-based practice under competent Cancer Management Teams. This helps us in delivering exemplary treatment to the patient in an environment that has consistently delivered an international standard of clinical outcomes.

Today, people from 147 countries come to India for cancer treatment at Apollo Cancer Centre. With the first and only Pencil Beam Proton Therapy Centre in South Asia & Middle East, Apollo Cancer Centre.

For media inquiries or further information, please contact: MSL
Jagan R | [email protected] | 9840966867
Samayeshwari Vithaspa | [email protected] | 9940032587
Nanda Gopal | [email protected] | 9176218089


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.